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Veliparib Plus Carboplatin and Paclitaxel Versus
Investigator’s Choice of Standard Chemotherapy
in Patients With Advanced Non–Squamous
Non–Small Cell Lung Cancer
Ramaswamy Govindan,1 Mike Lind,2 Amelia Insa,3 Saad A. Khan,4,†
Dmitry Uskov,5 Ali Tafreshi,6 Salih Guclu,7 Jair Bar,8,9 Terufumi Kato,10
Ki Hyeong Lee,11 Kazuhiko Nakagawa,12 Olfred Hansen,13,14 Bonne Biesma,15
Madan G. Kundu,16 Martin Dunbar,16 Lei He,16 Peter Ansell,16 Vasudha Sehgal,16
Xin Huang,16 Jaimee Glasgow,16 Bruce A. Bach16
Abstract
Patients with advanced non–squamous non–small cell lung cancers without oncogenic drivers have poor
treatment outcomes. Overall, no survival beneﬁt was observed in patients (N = 595) receiving veliparib plus
chemotherapy versus chemotherapy alone. However, in the LP52+ population (n = 80), patients receiving
veliparib plus chemotherapy trended toward improved survival. The LP52 signature may help predict patients
more likely to beneﬁt from veliparib.
Background: This open-label Phase III trial (NCT02264990) evaluated the PARP inhibitor, veliparib, combined with
carboplatin/paclitaxel versus chemotherapy alone for ﬁrst-line treatment of patients with advanced non–squamous non–
small cell lung cancers (NSCLC). A 52-gene expression classiﬁer (LP52) previously shown to identify patients more
likely to respond to veliparib was evaluated as a planned correlative analysis. Materials and Methods: Adult current or
former smokers with advanced non–squamous NSCLC were randomized 1:1 to veliparib (120 mg daily for 7 days/cycle)
with carboplatin and paclitaxel or to investigators’ choice of platinum doublet chemotherapy (up to 6, 21-day cycles),
with optional pemetrexed maintenance. Prospective analysis of the LP52 signature was conducted using a clinical
Qiagen/HTG assay. The primary endpoint was overall survival (OS) in LP52+ patients. Results: Overall, 595 patients
received veliparib + carboplatin/paclitaxel (n = 298) or chemotherapy alone (n = 297); 13% (n = 40) in each arm were
LP52+. The primary endpoint was not met; median OS was 11.2 months with veliparib + carboplatin/paclitaxel versus
9.2 months with chemotherapy alone in the LP52+ subgroup (hazard ratio [HR] 0.644, 95% conﬁdence interval [CI]:
0.396-1.048; P = .113). In the overall population, median OS was 12.1 months in both arms (HR 0.986, 95% CI: 0.8271.176; P = .846). No new safety signals were observed. Conclusion: In patients with non–squamous NSCLC, there
was no signiﬁcant improvement in OS with veliparib + carboplatin/paclitaxel versus chemotherapy alone, although a
trend toward improved OS in the LP52+ population suggests this subgroup may beneﬁt from veliparib. Statistical power
was limited due to the small sample size.
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Introduction
Lung cancer is the leading cause of cancer-related mortality
worldwide and incidence rates are intrinsically linked to smoking.1
The vast majority of lung cancers are non–small cell lung cancers
(NSCLCs) which are divided into squamous and non–squamous
histology. Non–squamous NSCLC include adenocarcinoma, which
is the most common NSCLC subtype, and large cell carcinoma.2 , 3
Targeted therapies are the current standard of care for patients with
advanced, oncogene-driven non–squamous NSCLC.4 However,
for patients with advanced NSCLC who do not have actionable
oncogene mutations, platinum-based chemotherapy is the mainstay
of first-line treatment, and a substantial proportion of these patients
die within 3 years of diagnosis.5-7 Identifying optimal treatments for
patients with non–squamous NSCLC that is not oncogene-driven
is a key challenge in improving outcomes for these patients.
Poly (adenosine diphosphate-ribose) polymerase (PARP) enzymes
facilitate the repair of DNA damage.8 , 9 PARP inhibitors have
shown benefit in patients with tumors that exhibit deficiency
in homologous recombination DNA repair, including loss of
BRCA1/2 function10-14 and more recently have demonstrated activity against homologous recombination-competent tumors, including NSCLC.15 Veliparib is a potent, oral PARP1/2 inhibitor which
has demonstrated antitumor activity as monotherapy16 , 17 and in
combination with chemotherapy where it has enhanced the activity of platinum-based agents in preclinical models and in patients
with solid tumors.18-21 A randomized, Phase II, placebo-controlled
trial in patients with untreated advanced or metastatic NSCLC
showed a trend toward improved progression-free survival (PFS)
and overall survival (OS) with the addition of veliparib to carboplatin/paclitaxel,21 particularly in patients who were smokers.21
To facilitate the optimization of therapy, gene expression panelbased classification methods are being developed, validated, and
applied, to better characterize poorly differentiated tumors, identify
candidate prognostic biomarkers and direct targeted therapies.22 , 23
Among these is a 57-gene lung subtyping panel (LSP) of 52 classification genes and 5 housekeeping genes which has demonstrated
the ability to reproducibly differentiate squamous, adenocarcinoma,
and neuroendocrine lung cancers, including poorly differentiated
tumors.24-26 The LSP was used to identify patients with poor
prognosis in 3 independent NSCLC cohorts (N > 1000) which
supports the potential for LSP as a gene expression-based prognostic marker in this population.25
The use of archived specimens from large perspective clinical
trials has been proposed as a means to assess the medical utility of
prognostic and predictive biomarkers.27 We developed a new binary
expression classification derived from the 52 classification genes of
the LSP assay, referred to herein as Lung Panel 52 (LP52) (a list
of the 52 genes included is provided in Supplementary Methods 2,
Table 1). The predictive value of the LP52 classifier for improved
efficacy with veliparib was initially identified in exploratory analyses
of a Phase II veliparib trial in NSCLC (NCT01560104)21 and was
verified in a Phase III veliparib trial in squamous NSCLC, which
demonstrated a potential benefit in overall survival (OS) in patients
E-mail contact: rgovindan@wustl.edu
†

Present address: Stanford University, 450 Serra Mall, Stanford, CA 94305, USA

with an LP52 positive (LP52+) status receiving veliparib.28 Following prospective-retrospective verification of the LP52 classifier,27 we
hypothesized that this predictive value of LP52 to identify patients
who have poorer outcomes and who may demonstrate an improved
response to veliparib therapy may also be applicable to patients with
non–squamous NSCLC.
This Phase III, randomized trial aimed to evaluate the efficacy
and safety of veliparib combined with carboplatin/paclitaxel versus
investigator’s choice of standard chemotherapy as first-line treatment
for patients with metastatic or advanced non–squamous NSCLC,
including those who were LP52+. LP52 was evaluated prospectively
as part of planned analyses. The study preceded the approval of
immunotherapy as first-line treatment for non–squamous NSCLC,
with the first visit occurring in September 2014 when platinumbased doublet chemotherapy, followed by maintenance treatment
(such as pemetrexed), was standard of care.29

Materials and Methods
Patient Selection
Patients at least aged 18 years with a life expectancy of
greater than 12 weeks and cytologically or histologically confirmed
advanced or metastatic non–squamous NSCLC not amenable to
surgical resection or radiation with curative intent at screening
were eligible. Patients with mixed histology tumors were eligible
if the tumor was predominantly non–squamous histology and did
not include tumor cells with small cell histology. Recruitment was
restricted to patients who were current or former smokers with at
least 1 unidimensional measurable NSCLC lesion on a computed
tomography scan as defined by Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.1, no history of brain metastases
or evidence of central nervous system tumors at screening, and an
Eastern Cooperative Oncology Group Performance Score (ECOG
PS) of 0-1. Patients must have consented to provide archived tissue
or a cytology sample of NSCLC tumor for analysis, if available.
Exclusion criteria included peripheral neuropathy of Grade 2 or
above, squamous NSCLC or tumors with untreated EGFR mutation
and/or ALK gene rearrangement, and a history of seizure within
the last year. Prior cytotoxic chemotherapy or chemoradiotherapy
for advanced NSCLC and recent radiotherapy were not permitted.
Additional eligibility criteria are listed in Supplementary Methods.

Study Design
This Phase III, randomized, open-label, multicenter study
(NCT02264990) was conducted across 131 sites in 20 countries
(enrolled from 2014 to 2016) and was performed in accordance
with the protocol, International Council for Harmonization of
Technical Requirements for Pharmaceuticals for Human Use, applicable regulations and guidelines governing clinical study conduct,
and ethical principles that have their origin in the Declaration of
Helsinki. Each patient was required to give their informed consent.
Patients were randomized 1:1 to receive veliparib + carboplatin/paclitaxel or chemotherapy alone (investigator’s choice
of carboplatin/paclitaxel, cisplatin/pemetrexed, or carboplatin/pemetrexed) by an interactive response technology system
with use of permuted blocks within strata. Variable block sizes
of 2 and 4 were used. Randomization was stratified by smoking
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Table 1

Baseline Demographics and Disease Characteristics
LP52+ population
Veliparib + carboplatin
/paclitaxel N = 40

Chemotherapy
alone N = 40

Overall population
Veliparib + carboplatin
/paclitaxel N = 298

Chemotherapy
alone N = 297

Gender
Male

29 (73)

28 (70)

206 (69)

207 (70)

Female

11 (28)

12 (30)

92 (31)

90 (30)

White

31 (78)

27 (68)

229 (77)

233 (78)

Black

3 (8)

3 (8)

11 (4)

11 (4)

Asian

6 (15)

10 (25)

57 (19)

53 (18)

Other

0

0

1 (< 1)

0

61 (37-79)

68 (39-81)

63 (27-81)

64 (34-85)

6 (15)

7 (18)

35 (12)

37 (12)

21 (53)

26 (65)

157 (53)

177 (60)

Eastern Europe/Russia

13 (33)

4 (10)

88 (30)

68 (23)

Asia (excluding Japan)

0

3 (8)

18 (6)

15 (5)

Current smokerb

24 (60)

21 (53)

152 (51)

153 (52)

Former smokerc

16 (40)

19 (48)

146 (49)

144 (48)

0

11 (28)

14 (35)

116 (39)

113 (38)

1

29 (73)

26 (65)

182 (61)

184 (62)

Ethnicity

Median age, y (range)
Geographic region
Japan
United States, Western Europe, Australia,
and Canada

Smoking statusa

ECOG performance statusa

Number of involved organ sitesd
1-2

24 (60)

22 (55)

169 (57)

162 (55)

>2

15 (38)

18 (45)

125 (43)

134 (45)

Missing

1

0

4

1

Locally advanced

8 (20)

4 (10)

38 (13)

38 (13)

Metastatic

32 (80)

35 (90)

257 (87)

255 (87)

Tumor stage

0

1

3

4

Median tumor burden, mm (range)

Missing

68 (10-302)

78 (12-227)

73 (10-367)

75 (10-288)

Median time from diagnosis to randomization,
mo (range)

2.4 (0.8-91.3)

1.7 (0.9-42.8)

2.0 (0.4-121.3)

1.9 (0.3-100.5)

40 (100)

40 (100)

40 (13)

40 (13)

0

0

74 (25)

53 (18)

0

0

184 (62)

204 (69)

LP52 status
LP52+
LP52−
LP52 unknown/missing

Abbreviations: ECOG = Eastern Cooperative Oncology Group; LP52 = Lung Panel 52. Data reported as n (%), unless otherwise stated.
Percentages calculated on non–missing values.
a
Based on interactive response technology data and used for stratiﬁcation in randomization.
b
> 100 smoking events over lifetime and smoked within the last year.
c
> 100 smoking events over lifetime and not smoked within the last year.
d
Collected from baseline tumor assessment.

status (current vs. former), investigator’s preferred platinum doublet
therapy (carboplatin/paclitaxel vs. cisplatin/pemetrexed vs. carboplatin/pemetrexed), gender (male vs. female), and ECOG PS
(0 vs. 1).
Oral veliparib was administered on Days −2-5 (7 days, beginning 2 days prior to the first dose of carboplatin/paclitaxel) at a
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dose of 120 mg twice daily of each 21-day cycle. Carboplatin (area
under the curve [AUC] 6 mg/mL/min) and paclitaxel (200 mg/m2 )
were administered on Day 1 of each 21-day cycle. Within the
chemotherapy-alone arm, carboplatin (AUC 6 mg/mL/min) and
paclitaxel (200 mg/m2 ), or cisplatin (75 mg/m2 ) and pemetrexed
(500 mg/m2 ), or carboplatin (AUC 6 or AUC 5 mg/mL/min) and

Ramaswamy Govindan et al
pemetrexed (500 mg/m2 ) were administered on Day 1 of each 21day cycle. Treatment was continued for a maximum of 6 cycles,
or until discontinuation due to toxicity or radiographic progression. Dose delays or modifications due to study drug toxicities were
permitted. Eligible patients were encouraged to receive maintenance
pemetrexed (500 mg/m2 ) on Day 1 of each 21-day cycle following
completion of platinum doublet therapy.
Tumor assessments were conducted at baseline, prior to Cycles
3 and 5, and every 9 weeks during maintenance therapy until
unacceptable toxicity or disease progression. Patients who did not
receive maintenance therapy were assessed every 9 weeks for 1 year,
then every 12 weeks until progression. During survival follow-up, all
patients were contacted every 2 months until death, loss to followup, or study termination.

Biomarker-defined Population
LP52 analysis was carried out on available tumor samples as
previously described.24 , 28 The current analysis used the same set
of genes as the LP52 classifier assay in M11-089 and the original
LSP.24 , 28 While retrospective use of LP52 in M11-089 was based on
an RNA sequencing (RNAseq) platform normalized within M11089 samples, to define LP52+ patients for the primary analysis of
M14-359, we collaborated with Qiagen (Hilden, Germany), and
HTG Molecular Diagnostics (Tucson, AZ) to develop an Investigational Use Only (IUO) RNA assay for LP52 classification. The IUO
version of LP52 is based on HTG EdgeSeq (or HTGseq) technology, which uses a quantitative nuclease protection assay chemistry
combined with next-generation sequencing to produce a simple
and reproducible platform that is more compatible with clinical use
than RNAseq. The evolution of LP52 is illustrated in Supplementary
Figure 1.
To develop the HTGseq-based IUO assay, a cohort of 422 lung
cancer tissues of known histology were procured and profiled with
both RNAseq and HTGseq. This cohort was divided into independent training (n = 327) and testing (n = 95) sets. An HTGseqbased classifier was developed using the training set to maximize
the concordance of the LP52 assignment between the 2 platforms.
The concordance rate, assessed using the testing set, is 85.7%
in squamous histology, and 75.0% in adenocarcinoma histology.
Unlike RNAseq-based calling, the IUO calling for each sample does
not require clinical histology information and does not require batch
normalization.
Additional information on the LP52 assay composition, development, and verification is provided in Supplementary Methods 2.

Endpoints
The primary endpoint was OS with veliparib + carboplatin/paclitaxel compared with chemotherapy alone in LP52+
patients. OS was defined as the number of days from the date
of randomization to the date of death. The primary endpoint
was amended from OS in the current smoker population after all
patients had been randomized, but prior to analysis of outcomes,
and before results of the LP52 assay were available. This change was
to enable the prospective application of a biomarker assay following
the emergence of data from a Phase II study of veliparib + carboplatin/paclitaxel in NSCLC (M10-898; NCT01560104) and a

Phase III study of veliparib + chemotherapy in squamous NSCLC
(M11-089; NCT02106546) that suggested the assay may have
utility across NSCLC subtypes, with LP52 positivity identifying
patients more likely to benefit from veliparib treatment.28
Secondary endpoints included OS in the overall population,
PFS in LP52+ patients and the overall population, and objective
response rate (ORR) in LP52+ patients and the overall population with veliparib + carboplatin/paclitaxel versus chemotherapy
alone. PFS was defined as the time from randomization to disease
progression (within 26 weeks from last tumor assessment) or death
from any cause (within 12 weeks of the last tumor assessment)
according to RECIST version 1.1, as assessed by the local investigator. Other efficacy endpoints were duration of response (DoR),
depth of response, change in ECOG PS from baseline, and change
from baseline in quality of life (QoL) scores compared between
the 2 study arms in LP52+ patients and the overall population.
Safety parameters were evaluated continuously during the study and
adverse events (AEs) were assessed according to the National Cancer
Institute (NCI) Common Terminology Criteria for Adverse Events
(CTCAE) Version 4.0.

Statistical Analysis
The study’s original statistical design aimed to enroll 300 current
smoker patients to accrue 210 OS events to provide at least 90%
power at a 1-sided 0.025 α level (assuming a hazard ratio [HR] of
0.64) to detect a significant treatment effect. It was anticipated that
225 former smokers would be enrolled alongside current smokers
for a total of approximately 525 patients.
The primary endpoint was amended from a non–biomarker
selected non–squamous NSCLC population to the LP52+ population after the trial was fully enrolled. Accordingly, approximately
76% of total enrolled patients were estimated to have evaluable
tumor tissue sample available for LP52 profiling with 50% LP52
positivity rate. Assuming 80% OS event rate, 180 OS events were
expected that would give 82% power to detect significant treatment
effect in LP52+ population. The data cutoff for the efficacy analyses
reported in this manuscript was July 15, 2019. For all other analyses, all data accrued up to the database lock date of November 14,
2019 were used.
Unless otherwise noted, statistical significance was determined
by a 2-sided P value ≤ .05 (corresponding to 1-sided α
level of 0.025) for all statistical analyses. Efficacy analyses were
performed on the intention to treat (ITT) population including all randomized patients. Safety analyses were performed on
the as-treated population including all randomized patients who
received at least 1 dose of study drug. For the primary analysis, between-group differences were determined with a 2-sided logrank test, stratified by ECOG PS (0, 1), investigator’s preferred
chemotherapy (carboplatin/paclitaxel, cisplatin/pemetrexed, carboplatin/pemetrexed), and gender. HRs and 95% confidence intervals (CI) were estimated using a stratified Cox proportional hazard
model. The Kaplan–Meier method was used to generate time-toevent curves and to calculate median values. If statistical significance was shown for the primary endpoint analysis (ie, OS in
LP52+ patients), secondary endpoints were to be tested using a
fixed-sequence testing procedure in the following order: PFS in
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Figure 1

Patient disposition. Abbreviations: AE = adverse event; C/P = carboplatin/paclitaxel; LP52 = Lung Panel 52;
QC = quality control.

LP52 analysis
• Sample available for analysis: 58%
• QC pass: 38%
• LP52+: 13% (n=40)
• LP52−: 25% (n=74)
• Unknown/missing: 62% (n=184)

595 patients randomized

Veliparib + C/P
n=298

LP52 analysis
• Sample available for analysis: 54%
• QC pass: 31%
• LP52+: 13% (n=40)
• LP52−: 18% (n=53)
• Unknown/missing: 69% (n=204)

Investigator’s choice
n=297

Did not receive
study drug: 5

Did not receive
study drug: 9

Received ≥1 dose of study drug
n=293

Completed 6 cycles of
veliparib + C/P:
n=145 (49%)

Completed 6 cycles of
investigator’s choice chemotherapy:
n=139 (47%)

Discontinued:
Veliparib
• AE related to progression: 6%
• AE not related to progression: 15%
• Withdrew consent: 4%
• Progressive disease: 20%
• Other: 7%
Study
• Withdrew consent: 2%
• Lost to follow-up: 1%
• Death: 84%
• Other: <1%

Discontinued:
Investigator’s choice chemotherapy
• AE related to progression: 6%
• AE not related to progression: 16%
• Withdrew consent: 2%
• Progressive disease: 19%
• Other: 11%
Study
• Withdrew consent: 1%
• Lost to follow-up: <1%
• Death: 86%
• Other: 0

Pemetrexed
maintenance
n=123

LP52+ patients, ORR in LP52+ patients, OS in all patients, PFS
in all patients, and ORR in all patients. HRs were estimated using
a covariate-adjusted Cox regression model with covariates being
ECOG PS, investigator’s preferred chemotherapy, and gender.
Analyses were done with SAS (Cary, NC) version 9.4 under the
UNIX operating system.

Results
Patients
In total, 595 patients were randomized to receive
veliparib + carboplatin/paclitaxel (n = 298) or chemotherapy alone (n = 297). Of those who received chemotherapy
alone, 71 (24%) received carboplatin/paclitaxel, 95 (32%)
received cisplatin/pemetrexed, and 131 (44%) received carboplatin/pemetrexed. Just under half of the patients in each arm
completed the maximum 6 cycles of scheduled therapy; the primary
reason for early discontinuation was progressive disease (Figure 1).
Pemetrexed maintenance therapy was received by 123 (41%)
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Received ≥1 dose of study drug
n=288

Pemetrexed
maintenance
n=148

patients in the veliparib + carboplatin/paclitaxel arm and 148
(50%) patients in the chemotherapy-alone arm.
The percentage of patients who were able to provide a tumor
tissue sample for analysis was less than the 76% that was estimated;
331 patients (56%) in the overall population provided a tumor
tissue sample sufficient for LP52 evaluation (including > 50%
tumor content), and 207 of these yielded analytically valid results
(classified as LP52+ or LP52−); 388 patients were not able to
provide tumor tissue that met these criteria and were classified
unknown/missing. Among the total enrolled patients in each treatment arm, 13% were LP52+ in both the veliparib + carboplatin/paclitaxel arm and the chemotherapy-alone arm; 25% and
18% were LP52− in the veliparib + carboplatin/paclitaxel arm and
the chemotherapy-alone arm, respectively.
The majority of patients were male (69%) and White (78%),
and approximately half were current smokers (51%). There were
no clinically meaningful differences in baseline demographics or
disease characteristics between treatment arms in the overall or
LP52+ populations (Table 1). Baseline demographics and charac-

Ramaswamy Govindan et al
Figure 2

Kaplan–Meier curves for OS in the (A) LP52+ population and (B) Overall Population. Abbreviations:
C/P = carboplatin/paclitaxel; CI = confidence interval; HR = hazard ratio; LP52 = Lung Panel 52; OS = overall survival.

teristics were also balanced between the 3 regimens within the
chemotherapy-alone group, with the exception of a higher proportion of patients enrolled from Eastern Europe and Russia in the
carboplatin/paclitaxel group (Supplementary Table 1).

Efficacy
At the time of the primary data cutoff (July 15, 2019), median
OS follow up within the veliparib + carboplatin/paclitaxel and
chemotherapy-alone arms was 45.3 months and 44.5 months,
respectively, in the LP52+ population, and 44.6 and 45.4 months
in the overall population. There were 71 OS events in the 80 LP52+
patients across both treatment arms, representing 89% maturity.
The primary efficacy endpoint of OS in LP52+ patients was not
met; there was no statistically significant OS benefit for the patients
with LP52 positivity who received veliparib + carboplatin/paclitaxel
(n = 40) compared with chemotherapy alone (n = 40), despite
an early and consistent separation of survival curves. Median OS
was 11.2 months in the veliparib + carboplatin/paclitaxel arm and

9.2 months in the chemotherapy-alone arm (HR: 0.644 [95% CI:
0.396-1.048], stratified log-rank 2-sided P = .113) (Figure 2A).
Because the primary endpoint was not met, analyses of secondary
efficacy endpoints were carried out in a descriptive manner. The
trend for OS benefit observed in the LP52+ patients was not
observed in the overall population; median OS was 12.1 months
in both arms (HR: 0.986 [95% CI: 0.827-1.176]; nominal 2-sided
P = .846) (Figure 2B). Similarly, there was no trend toward an
OS benefit in LP52− patients, or those with unknown or missing
LP52 status (Supplementary Figure 2). Median OS was 12.1 months
in both arms for LP52– patients (HR: 0.922 [95% CI: 0.6231.366]; nominal 2-sided P = .996). For those with unknown or
missing LP52 status, OS was 12.3 months and 13.0 months in the
veliparib + carboplatin/paclitaxel and chemotherapy-alone arms,
respectively (HR: 1.086 [95% CI: 0.873-1.350]; nominal 2-sided
P = .364).
PFS directionally favored veliparib + carboplatin/paclitaxel
versus chemotherapy alone in the LP52+ population, with medians
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Figure 3

Kaplan–Meier curves for PFS in the (A) LP52+ population and (B) Overall Population. Abbreviations:
C/P = carboplatin/paclitaxel; CI = confidence interval; HR = hazard ratio; LP52 = Lung Panel 52; OS = overall
survival; PFS = progression-free survival.

of 6.3 and 5.2 months, respectively (HR: 0.647 [95% CI: 0.3881.080]; nominal 2-sided P = .260; Figure 3A). In the overall population, PFS did not improve at 5.9 months and 6.7 months in
the veliparib + carboplatin/paclitaxel versus chemotherapy-alone
arms, respectively (HR: 1.035 [95% CI: 0.867-1.235]; nominal 2sided P = .473) (Figure 3B). Median PFS was 5.6 months in the
veliparib + carboplatin/paclitaxel arm, versus 7.2 months in the
chemotherapy-alone arm for LP52− patients (HR: 1.066; 95% CI:
0.687-1.654) and 6.0 months versus 6.9 months amongst those
with unknown or missing LP52 status (HR: 1.136; 95% CI: 0.9141.413) (data not shown).
Among the LP52+ patients, ORR was 23% in the
veliparib + carboplatin/paclitaxel arm and 30% in the
chemotherapy-alone arm (Table 2). All responses were partial.
Stable disease as best response was achieved by 43% of patients
in the veliparib + carboplatin/paclitaxel arm and 38% in the
chemotherapy-alone arm. In the overall population, ORR was
achieved by 26% of patients in the veliparib + carboplatin/paclitaxel
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arm and 29% of patients in the chemotherapy-alone arm. Two
patients in each arm achieved complete response. Similar proportions of patients achieved stable disease as best response (43%
in the veliparib + carboplatin/paclitaxel arm and 40% in the
chemotherapy-alone arm).
No clinically meaningful differences were observed between treatment arms for DoR. For patients who achieved an objective response
within the overall population (n = 164), median DoR was 7.3
months in the veliparib + carboplatin/paclitaxel arm, and 6.6
months in the chemotherapy-alone arm. Among responders in the
LP52+ population (n = 21), median DoR was 9.0 months in
the veliparib + carboplatin/paclitaxel arm, and 6.1 months in the
chemotherapy-alone arm.
Approximately half of all patients received posttreatment anti–
cancer therapy, which was comparable between treatment arms
(Supplementary Table 2).
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Table 2

ORR in LP52+ and Overall Populations
LP52+ population
Veliparib + carboplatin
/paclitaxel n = 40

Chemotherapy
alone n = 40

Overall population
Veliparib + carboplatin
/paclitaxel n = 298

Chemotherapy
alone n = 297

Objective response, n (%)
CR

0

0

2 (1)

2 (1)

PR

9 (23)

12 (30)

76 (26)

84 (28)

ORR (CR+PR)

9 (23)

12 (30)

78 (26)

86 (29)

Odds ratio (95% CI)
P value

0.66 (0.23-1.90)

0.86 (0.59-1.24)

.445

.409

Best response, n (%)
CR

0

0

2 (1)

4 (1)

PR

13 (33)

14 (35)

103 (35)

113 (38)

SD

17 (43)

15 (38)

127 (43)

119 (40)

PD

7 (18)

4 (10)

34 (11)

34 (11)

Incomplete data

3 (8)

7 (18)

32 (11)

27 (9)

Abbreviations: CI = conﬁdence interval; CR = complete response; LP52 = Lung Panel 52; ORR = objective response rate; PD = progressive disease; PR = partial response; SD = stable disease.

Safety
Patients in the veliparib + carboplatin/paclitaxel arm received
a median of 5 cycles of veliparib, with a mean of 32 dosed days
(out of a maximum of 42). Chemotherapy exposure was comparable between the veliparib + carboplatin/paclitaxel arm (median of 5
cycles each for carboplatin/paclitaxel) and the chemotherapy-alone
arm (median of 5 cycles). Relative dose intensity was ≥ 94% for all
study drugs in the overall population.
The majority of patients experienced at least one AE (98%
in the veliparib + carboplatin/paclitaxel arm and 96% in the
chemotherapy-alone arm), the most common being alopecia (47%),
peripheral sensory neuropathy (45%), and anemia (41%) in the
veliparib + carboplatin/paclitaxel arm, and nausea (47%), anemia
(42%), and neutropenia (33%) in the chemotherapy-alone arm
(Table 3). AEs occurring more frequently with veliparib + carboplatin/paclitaxel and with a ≥ 10% difference between the randomized treatment arms included alopecia (47% and 12%, respectively)
and peripheral sensory neuropathy (45% and 15%), both of which
are toxicities associated with paclitaxel (received by all patients in
veliparib arm and < 25% of patients in the chemotherapy-alone
arm). AEs occurring within the chemotherapy-alone arm reflected
the distinct safety profiles of each regimen (Supplementary Table 3).
In the veliparib + carboplatin/paclitaxel treatment arm, AEs
leading to discontinuation of veliparib, carboplatin or paclitaxel
occurred in 27% of patients, with the most common being peripheral sensory neuropathy (5%), malignant neoplasm progression
(4%), and anemia (3%). Within the chemotherapy-alone arm, AEs
leading to discontinuation were experienced by 25% of patients
overall, and this was broadly comparable across regimens. In the
veliparib + carboplatin/paclitaxel arm, AEs that led to delay or
reduction of veliparib occurred in 25% of patients, and AEs leading
to delay or reduction of carboplatin/paclitaxel dosing occurred in
37%/42% of patients. In the chemotherapy-alone arm, 45% of
patients experienced an AE that led to delay or reduction of dose; the

most frequently reported of these were hematologic across regimens,
and treatment arms.
AEs considered veliparib, carboplatin, or paclitaxel-related
were experienced by 59%, 89%, and 91% of patients in the
veliparib + carboplatin/paclitaxel arm, respectively. Within the
chemotherapy-alone arm, AEs considered chemotherapy-related
were experienced by 89% of patients overall (77%/81%, 90%/87%,
and 91%/91% in those who received carboplatin/paclitaxel,
cisplatin/pemetrexed, and carboplatin/pemetrexed, respectively).
Grade 3 or 4 AEs were experienced by 68% of patients in
the veliparib + carboplatin/paclitaxel arm and 57% of patients in
the chemotherapy-alone arm, the majority of which were hematologic (Table 3). Only neutropenia occurred at ≥ 10% difference between treatment arms. Serious AEs were experienced by
41% of patients in the veliparib + carboplatin/paclitaxel arm and
34% in the chemotherapy-alone arm (Supplementary Table 4). The
most frequent of these that were considered study-drug related in
the veliparib + carboplatin/paclitaxel arm were febrile neutropenia, anemia, neutropenia, vomiting, and pneumonia, while the
most frequent considered related to doublet chemotherapy in the
chemotherapy-alone arm was anemia. AE-related deaths occurred
in 8% of patients in both treatment arms. Two deaths (0.7%)
were assessed as having a reasonable possibility of being related to
veliparib.

Discussion
The study did not meet its primary endpoint, with no significant
OS improvement observed with veliparib + carboplatin/paclitaxel
versus chemotherapy alone in LP52+ patients. The original primary
endpoint in the current smoker population was amended in light of
emerging data from LP52+ populations in other studies,28 which
occurred following randomization and treatment in this study. The
change in endpoint resulted in a smaller primary analysis population
(40 patients in each arm) which should be considered when inter-
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Table 3

TEAEs Occurring in ≥ 10% of Patients and Grade 3/4 TEAEs Occurring in ≥ 5% of Patients, in Any Treatment Arm
Veliparib + carboplatin
/paclitaxel N = 293

Any TEAE

Chemotherapy alone
N = 288

Any grade

Grade 3/4

Any grade

Grade 3/4

286 (98)

198 (68)

277 (96)

163 (57)

Alopecia

137 (47)

1 (< 1)

34 (12)

0

Peripheral sensory neuropathy

132 (45)

14 (5)

42 (15)

3 (1)

Anemia

119 (41)

49 (17)

122 (42)

47 (16)

Neutropenia

110 (38)

85 (29)

94 (33)

53 (18)

Nausea

89 (30)

5 (2)

134 (47)

7 (2)

Fatigue

80 (27)

5 (2)

91 (32)

10 (3)

Thrombocytopenia

78 (27)

20 (7)

60 (21)

26 (9)

Constipation

71 (24)

3 (1)

93 (32)

0

Decreased appetite

65 (22)

6 (2)

81 (28)

9 (3)

Diarrhea

53 (18)

6 (2)

49 (17)

4 (1)

Dyspnea

50 (17)

8 (3)

32 (11)

9 (3)

Leukopenia

45 (15)

20 (7)

40 (14)

13 (5)

Vomiting

45 (15)

3 (1)

78 (27)

7 (2)

Arthralgia

40 (14)

5 (2)

26 (9)

2 (1)

Myalgia

38 (13)

3 (1)

17 (6)

1 (< 1)

Insomnia

37 (13)

0

30 (10)

1 (< 1)

Asthenia

30 (10)

3 (1)

32 (11)

5 (2)

Cough

27 (9)

1 (< 1)

29 (10)

0

Pneumonia

25 (9)

18 (6)

13 (5)

7 (2)

Dysgeusia

19 (6)

0

29 (10)

0

Stomatitis

19 (6)

1 (< 1)

30 (10)

3 (1)

Febrile neutropenia

15 (5)

15 (5)

7 (2)

7 (2)

Pulmonary embolism

8 (3)

7 (2)

13 (5)

13 (5)

Abbreviation: TEAE = treatment emergent adverse event.

preting these data. With a valid sample availability rate of just 35%
and 80 LP52+ patients across the treatment arms, statistical power
was limited.
There was a trend for OS and PFS benefit with veliparib + carboplatin/paclitaxel compared with chemotherapy alone in the
LP52+ population, with an early, and consistent separation of
survival curves. In the overall population, these efficacy outcomes
were similar between treatment arms, and no clinically meaningful
differences were observed for ORR, DoR, and changes from baseline
in QoL and ECOG PS.
Exposure to chemotherapy was similar between treatment arms,
and across the regimens administered in the chemotherapy-alone
arm, with relative dose intensity ≥ 94% for all study drugs in the
overall population. Of note, planned exposure to veliparib was lower
than in other studies where veliparib was administered continuously
or as monotherapy.10 , 30 , 31
Veliparib demonstrated an acceptable safety profile, with no new
safety signals for the study combination. The higher frequency of
alopecia and peripheral neuropathy reported in the veliparib arm
may be a consequence of the higher proportion of patients who
received paclitaxel (100% of patients in the veliparib + carboplatin/paclitaxel arm versus 24% in the chemotherapy arms, respec-
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tively); this is reflected in the broadly comparable rates of these AEs
in the veliparib + carboplatin/paclitaxel and carboplatin/paclitaxel
arms. Hence, these data should be interpreted with caution.
Our results are consistent with those from a recent study that
evaluated veliparib + carboplatin/paclitaxel versus placebo + carboplatin/paclitaxel as first-line treatment for patients with advanced
squamous NSCLC, where no significant benefit was noted among
efficacy parameters in the overall population. However, among
the 360 patients evaluated for LP52, a trend for improved OS
was observed in the veliparib + carboplatin/paclitaxel arm with
∼34% decreased risk of death versus placebo in patients who
were LP52+.28 The current study provides promising evidence for
the potential of LP52 as a biomarker which may identify those
patients more likely to benefit from addition of veliparib to carboplatin/paclitaxel. In addition, the median OS for LP52+ and LP52–
subgroups within the chemotherapy-alone arm (9.2 months and
12.1 months, respectively) of this study suggests LP52 positivity
may be an indicator of poor prognosis, consistent with data from the
LSP signature.25 In development of the HTGseq-based IUO assay
using procured lung cancer tissue samples of known histology, the
concordance rate between RNAseq and HTGseq in the adenocarcinoma samples was 75%, which may limit the conclusions in this
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population; however, interestingly, the concordance rate was over
85% in the squamous, suggesting that this subgroup of patients may
be more reliably classified as LP52+ or LP52–.
Consistent with the findings in squamous NSCLC,28 LP52+
tumors in the current trial samples were identified to have high stem
score (Supplementary Figure 3A) and high p53 inactivation score
(Supplementary Figure 3B). This phenomenon was also observed in 2
independent squamous NSCLC cohorts: The Cancer Genome Atlas
program and a cohort of procured tissues to HTG classifier development (data not shown). Stem cell properties are intrinsically linked
to tissue lineage and differentiation status, and certain cancers may
revert to a molecular state reminiscent of tissue or embryonic stem
cells as they become more aggressive.32 PARP1/2 enzymes play a
role in maintaining the self-renewal potency of embryonic cells.33 , 34
LP52+ tumors may be more aggressive in nature. The antitumor
activity observed with veliparib in the LP52+ group may be due to
selective targeting of the cancer stem component, which is enriched
in this group.
At the time this study was initiated, platinum-based doublet
chemotherapy was the standard first-line treatment for non–
squamous NSCLC without a targetable EGFR or ALK
mutation.29 , 35 Since then, the treatment paradigm has evolved
and diversified with the approval of immunotherapies and
additional targeted therapies.4 Several studies have supported the
immunomodulating effects of PARP inhibition, which can potentially enhance the clinical response to immunotherapies.36-38 Based
on this rationale, several ongoing clinical trials are assessing the
efficacy, and safety of PARP inhibition combined with immunotherapy in lung cancer. The phase III KEYLYNK-006 and KEYLYNK008 trials are evaluating pembrolizumab plus platinum-based
regimen followed by pembrolizumab and maintenance olaparib in
non–squamous NSCLC and squamous NSCLC, respectively.39 , 40
The KEYLYNK-012 trial is another ongoing phase III trial, which
assesses the superiority of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without
olaparib versus concurrent chemoradiation followed by durvalumab
in patients with stage III NSCLC.41 The current therapeutic
landscape is heavily in flux and these ongoing trials will further
elucidate the potential benefit of PARP inhibition in NSCLC
patients in different settings. Furthermore, the optimal positioning of therapies, both currently available and in development, for
patients with non–squamous NSCLC without actionable alterations
may be facilitated by the identification of robust biomarkers.

Conclusions
No significant benefit was observed with the addition of veliparib
to carboplatin/paclitaxel compared with chemotherapy alone for the
treatment of patients with advanced or metastatic non–squamous
NSCLC, both in the overall population and the LP52+ population. However, an early and consistent trend for improved OS and
PFS was noted in the LP52+ population, supporting previous data
and suggesting that this genetic signature may identify a population of patients more likely to benefit from veliparib. Additional
research is required to further explore this in a larger, biomarkerselected population.

Clinical Practice Points
•

•

•

•

Platinum-based chemotherapy is one of the front-line therapies for patients with advanced non–small cell lung cancer
(NSCLC) without actionable oncogene mutations. However,
clinical outcomes are poor and there is an unmet clinical need
to improve treatment options for these patients
Biomarker studies are being developed to identify candidate
prognostic biomarkers and to direct targeted therapies. We previously developed Lung Panel 52 (LP52), derived from the 52 classification genes of the lung subtyping panel, and showed the predictive value of LP52 in identifying patients with poor prognosis and
improved response to PARP inhibitor treatment in exploratory
analyses of phase II and phase III trials
In this study, patients with advanced NSCLC, including those
who are LP52+, were randomized to receive veliparib combined
with carboplatin/paclitaxel or chemotherapy alone. While in
the overall population the progression free survival and overall
survival were similar between treatment arms, the LP52+ population showed a positive trend for these outcomes when receiving
veliparib plus carboplatin/paclitaxel compared with chemotherapy alone
This study showed evidence for the potential of LP52 as a predictive biomarker. LP52+ gene expression signature may help to
identify a subgroup of patients with poor prognosis and to predict
those more likely to benefit from the addition of PARP inhibition
to chemotherapy

Funding
This work was supported by AbbVie. The funder participated in
the study design, research, analysis, data collection, interpretation of
data, reviewing, and approval of the publication.

Data Sharing Statement
AbbVie is committed to responsible data sharing regarding the
clinical trials we sponsor. This includes access to anonymized,
individual, and trial-level data (analysis data sets), as well as other
information (eg, protocols, and Clinical Study Reports), as long as
the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed
products and indications.
This clinical trial data can be requested by any qualified
researchers who engage in rigorous, independent scientific
research, and will be provided following review and approval
of a research proposal and Statistical Analysis Plan (SAP) and
execution of a Data Sharing Agreement (DSA). Data requests
can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For
more information on the process, or to submit a request,
visit the following link: https://www.abbvie.com/our-science/
clinical- trials/clinical- trials- data- and- information- sharing/
data- and- information- sharing- with- qualified- researchers.html.

Author Contributions
R. Govindan: Conceptualization; Methodology; Formal analysis; Investigation; Resources; Writing - review & editing; Supervision; M. Lind: Investigation; Resources; Writing - review & editing;

Clinical Lung Cancer May 2022

223

Veliparib Plus Carboplatin and Paclitaxel Versus Investigator’s Choice
A. Insa: Investigation; Resources; Writing - review & editing; S.A.
Khan: Investigation; Resources; Writing - review & editing; D.
Uskov: Investigation; Resources; Writing - review & editing; A.
Tafreshi: Investigation; Resources; Writing - review & editing; S.
Guclu: Investigation; Resources; Writing - review & editing; J. Bar:
Investigation; Resources; Writing - review & editing; T. Kato: Investigation; Resources; Writing - review & editing; K.H. Lee: Investigation; Resources; Writing - review & editing; K. Nakagawa:
Investigation; Resources; Writing - review & editing; O. Hansen:
Investigation; Resources; Writing - review & editing; B. Biesma:
Investigation; Resources; Writing - review & editing; M.G. Kundu:
Formal analysis; Writing - review & editing; M. Dunbar: Formal
analysis; Writing - review & editing; L. He: Conceptualization;
Methodology; Formal analysis; Writing - review & editing; P. Ansell:
Conceptualization; Methodology; Formal analysis; Writing - review
& editing; V. Sehgal: Conceptualization; Methodology; Formal
analysis; Writing - review & editing; X. Huang: Conceptualization; Methodology; Formal analysis; Writing - review & editing; J.
Glasgow: Conceptualization; Methodology; Formal analysis; Writing
- review & editing; Supervision; B.A. Bach: Conceptualization;
Methodology; Formal analysis; Writing - review & editing; Supervision.

Disclosure
Ramaswamy Govindan: Consulting fees from GenePlus and
Horizon Pharmaceuticals (spouse conflict); Mike Lind: Travel
grant to ASCO; Amelia Insa: Consulting advisory role: BMS,
Boeringher, MSD, Pfizer, Roche; Expert testimony: Astra Zeneca,
BMS, Boeringher, MSD, Pfizer, Roche; Travel, accommodations, expenses; BMS, Boeringher, MSD, Pfizer, Roche; Saad A.
Khan: Consultant advisory role for Eisai, Foundation Medicine,
Roche; Dmitry Uskov: None; Ali Tafreshi: None ; Salih Guclu:
None; Jair Bar: Research funding from AstraZeneca, ImmuneAI,
MSD, OncoHost, Pfizer, and Roche; Consulting fees from
AstraZeneca, BMS, MSD, Pfizer, Roche, Takeda, Causalis, and
Novartis; Terufumi Kato: Honoraria and research funding from
AbbVie, Amgen, AstraZeneca, BMS, Chugai, Eli Lilly, Merck
Biopharma, MSD, Novartis, Ono, Pfizer, and Taiho. Honoraria
from Boehringer-Ingelheim, Daiichi-Sankyo, Nippon Kayaku,
and Takeda. Research funding from Regeneron; Ki Hyeong Lee:
Honoraria for advisory role from AstraZeneca, BMS, MSD, and
Pfizer; Kazuhiko Nakagawa: Honoraria and research funding from
AbbVie, Astellas, AstraZeneca, Bayer Yakuhin, BMS, Chugai,
Daiichi Sankyo, Eli Lilly Japan, Kyowa Kirin, Merck Serono/Merck
Biopharma, MSD, Nippon Boehringer Ingelheim, Novartis,
Ono, Pfizer Japan, Taiho, Takeda; Honoraria from 3H Clinical Trial, Amgen, Care Net, Hisamitsu, Kyorin, Medical Mobile
Communications, Medical Review Co, Medicus Shuppan Publishers, Nanzando, Nichi-Iko, Nikkei Business Publications, Nippon
Kayaku, Roche Diagnostics, Thermo Fisher Scientific, Yodosha,
Yomiuri Telecasting; Research funding from A2 Healthcare, CMIC
Shift Zero, Covance Japan, Eisai, EPS International, GlaxoSmithKline, ICON Japan, IQVIA Services Japan, Japan Clinical Research
Operations, Kissei, Medical Research Support, Mochida, Otsuka,
Parexel International, PPD-SNBL, PRA HealthSciences, Sanofi,
SymBio, Syneos Health, Sysmex; Other from Eli Lilly Japan,

224

Clinical Lung Cancer May 2022

Kyorin, Ono, Pfizer Japan, Takeda; Olfred Hansen: None; Bonne
Biesma: Consultant advisory role for Lilly, BMS, Roche; Martin
Dunbar, Lei He, Peter Ansell, Vasudha Sehgal, Xin Huang, Jaimee
Glasgow: Employees of AbbVie and may own stock or stock options;
Madan Kundu and Bruce Bach: Former employees of Abbvie and
may own AbbVie stock.

Acknowledgments
The authors wish to thank former AbbVie employee, Philip
Komarnitsky, for his clinical oversight. Medical writing support was
provided by Karen O’Leary, PhD, of Fishawack Communications
Ltd, and funded by AbbVie. All authors had access to relevant data
and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship.

Supplementary materials
Supplementary material associated with this article can be found,
in the online version, at doi:10.1016/j.cllc.2022.01.005.

References
1. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob
Health. 2019;85:8. doi:10.5334/aogh.2419.
2. Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent advances
in targetable therapeutics in metastatic non-squamous NSCLC. Front Oncol.
2016;6:112. doi:10.3389/fonc.2016.00112.
3. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future
advances. Transl Lung Cancer Res. 2016;5:288–300. doi:10.21037/tlcr.2016.06.07.
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice
Guidelines in Oncology: Non-Small Cell Lung Cancer. Plymouth Meeting, PA:
NCCN; 2020.
5. Ramalingam SS, Dahlberg SE, Belani CP, et al. Pemetrexed, bevacizumab, or the
combination as maintenance therapy for advanced nonsquamous non-small-cell
lung cancer: ECOG-ACRIN 5508. J Clin Oncol. 2019;37:2360–2367. doi:10.
1200/JCO.19.01006.
6. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell
lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lancet. 2019;393:1819–1830. doi:10.1016/S0140- 6736(18)32409- 7.
7. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with
carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone
as first-line treatment for metastatic non-squamous non-small-cell lung cancer
(IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol.
2019;20:924–937. doi:10.1016/S1470- 2045(19)30167- 6.
8. Amé JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays.
2004;26:882–893. doi:10.1002/bies.20085.
9. Otto H, Reche PA, Bazan F, Dittmar K, Haag F. Koch-Nolte F. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC
Genomics. 2005;6:139. doi:10.1186/1471- 2164- 6- 139.
10. Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy
and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381:2403–
2415. doi:10.1056/NEJMoa1909707.
11. Chopra N, Tovey H, Pearson A, et al. Homologous recombination DNA repair
deficiency and PARP inhibition activity in primary triple negative breast cancer.
Nat Commun. 2020;11:2662. doi:10.1038/s41467- 020- 16142- 7.
12. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy
(ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet.
2017;390:1949–1961. doi:10.1016/S0140- 6736(17)32440- 6.
13. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in
platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–2164.
doi:10.1056/NEJMoa1611310.
14. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line
maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–2428. doi:10.1056/
NEJMoa1911361.
15. Jiang Y, Dai H, Li Y, et al. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer. Int J Cancer. 2019;144:1092–
1103. doi:10.1002/ijc.31770.
16. Steffensen KD, Adimi P, Jakobsen A. Veliparib monotherapy to patients with
BRCA germ line mutation and platinum-resistant or partially platinum-sensitive
relapse of epithelial ovarian cancer: a phase I/II study. Int J Gynecol Cancer.
2017;27:1842–1849. doi:10.1097/IGC.0000000000001089.
17. Villalona-Calero MA, Duan W, Zhao W, et al. Veliparib alone or in combination with mitomycin C in patients with solid tumors with functional deficiency

Ramaswamy Govindan et al
18.

19.
20.

21.
22.
23.
24.
25.
26.

27.
28.

29.
30.

31.

in homologous recombination repair. J Natl Cancer Inst. 2016;108:djv437. doi:10.
1093/jnci/djv437.
Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13:2728–2737. doi:10.1158/1078-0432.
CCR- 06- 3039.
Owonikoko TK, Zhang G, Deng X, et al. Poly (ADP) ribose polymerase enzyme
inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in
small cell lung cancer. Cancer Med. 2014;3:1579–1594. doi:10.1002/cam4.317.
Wahner Hendrickson AE, Menefee ME, Hartmann LC, et al. A phase I clinical
trial of the poly(ADP-ribose) polymerase inhibitor veliparib and weekly topotecan
in patients with solid tumors. Clin Cancer Res. 2018;24:744–752. doi:10.1158/
1078- 0432.CCR- 17- 1590.
Reck M, Blais N, Juhasz E, et al. Smoking history predicts sensitivity to PARP
inhibitor veliparib in patients with advanced non-small cell lung cancer. J Thorac
Oncol. 2017;12:1098–1108. doi:10.1016/j.jtho.2017.04.010.
Sherafatian M, Arjmand F. Decision tree-based classifiers for lung cancer diagnosis
and subtyping using TCGA miRNA expression data. Oncol Lett. 2019;18:2125–
2131. doi:10.3892/ol.2019.10462.
Li D, Yang W, Zhang Y, et al. Genomic analyses based on pulmonary adenocarcinoma in situ reveal early lung cancer signature. BMC Med Genomics.
2018;11(Suppl 5):106. doi:10.1186/s12920- 018- 0413- 3.
Wilkerson MD, Schallheim JM, Hayes DN, et al. Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens. J Mol Diagn.
2013;15:485–497. doi:10.1016/j.jmoldx.2013.03.007.
Mayhew G, Hayes N, Perou C, Lai-Goldman M, Faruki H. Survival differences
of adenocarcinoma lung tumors with squamous cell carcinoma or neuroendocrine
profiles by gene expression subtyping. J Thorac Oncol. 2015;10:S264.
Faruki H, Mayhew GM, Fan C, et al. Validation of the lung subtyping panel
in multiple fresh-frozen and formalin-fixed, paraffin-embedded lung tumor gene
expression data sets. Arch Pathol Lab Med. 2016;140:536–542. doi:10.5858/arpa.
2015- 0113- OA.
Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of
prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101:1446–1452.
doi:10.1093/jnci/djp335.
Ramalingam SS, Novello S, Guclu SZ, et al. Veliparib in combination with
platinum-based chemotherapy for first-line treatment of advanced squamous
cell lung cancer: a randomized, multicenter phase iii study. J Clin Oncol.
2021;39:3633–3644. doi:10.1200/JCO.20.03318.
Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer
(NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol. 2014;25(Suppl 3):iii27–iii39. doi:10.1093/annonc/mdu199.
Han HS, Dieras V, Robson M, et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with
BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Ann Oncol. 2018;29:154–161. doi:10.1093/annonc/mdx505.
Coleman RL, Sill MW, Bell-McGuinn K, et al. A phase II evaluation of the potent,
highly selective PARP inhibitor veliparib in the treatment of persistent or recur-

32.
33.

34.
35.
36.
37.
38.
39.

40.

41.

rent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who
carry a germline BRCA1 or BRCA2 mutation - An NRG oncology/gynecologic
oncology group study. Gynecol Oncol. 2015;137:386–391. doi:10.1016/j.ygyno.
2015.03.042.
Malta TM, Sokolov A, Gentles AJ, et al. Machine learning identifies stemness
features associated with oncogenic dedifferentiation. Cell. 2018;173:338–354
e315. doi:10.1016/j.cell.2018.03.034.
Lai YS, Chang CW, Pawlik KM, Zhou D, Renfrow MB, Townes TM. SRY
(sex determining region Y)-box2 (Sox2)/poly ADP-ribose polymerase 1 (Parp1)
complexes regulate pluripotency. Proc Natl Acad Sci U S A. 2012;109:3772–3777.
doi:10.1073/pnas.1108595109.
Weber FA, Bartolomei G, Hottiger MO, Cinelli P. Artd1/Parp1 regulates reprogramming by transcriptional regulation of Fgf4 via Sox2 ADP-ribosylation. Stem
Cells. 2013;31:2364–2373. doi:10.1002/stem.1507.
Besse B, Adjei A, Baas P, et al. 2nd ESMO consensus conference on lung cancer:
non-small-cell lung cancer first-line/second and further lines of treatment in
advanced disease. Ann Oncol. 2014;25:1475–1484. doi:10.1093/annonc/mdu123.
Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1
expression and enhances cancer-associated immunosuppression. Clin Cancer Res.
2017;23:3711–3720. doi:10.1158/1078- 0432.ccr- 16- 3215.
Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD. DNA damage
and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7:675–
693. doi:10.1158/2159- 8290.cd- 17- 0226.
Sen T, Rodriguez BL, Chen L, et al. Targeting DNA damage response promotes
antitumor immunity through STING-mediated T-cell activation in small cell lung
cancer. Cancer Discov. 2019;9:646–661. doi:10.1158/2159- 8290.cd- 18- 1020.
Gray JE, Owonikoko TK, Kato T, et al. Randomized phase III study of firstline pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and
maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous
non-small cell lung cancer (NSCLC): KEYLYNK-006. J Clin Oncol. 2020;38
TPS9632-TPS9632. doi:10.1200/JCO.2020.38.15_suppl.TPS9632.
Gray JE, Owonikoko TK, Kato T, et al. 1418TiP Randomized, placebo-controlled
phase III study of 1L pembrolizumab (Pembro) plus carboplatin/taxane followed
by pembro with or without maintenance olaparib in patients (Pts) with metastatic
squamous non-small cell lung cancer (sqNSCLC): KEYLYNK-008. Ann Oncol.
2020;31:S896. doi:10.1016/j.annonc.2020.08.1732.
Jabbour SK, Cho BC, Bria E, et al. Phase 3 study of pembrolizumab with
concurrent chemoradiation therapy followed by pembrolizumab with or without
olaparib versus concurrent chemoradiation therapy followed by durvalumab in
unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK012. J Clin Oncol. 2021;39 TPS8580-TPS8580. doi:10.1200/JCO.2021.39.15_
suppl.TPS8580.

Clinical Lung Cancer May 2022

225

